Remarkably, the proportion of ILD vs other events exponentially increased in 2009, even before the FDA warning; this trend can be potentially interpreted as a consequence of the increasing uptake of CDK4/6 inhibitors worldwide, especially in progressively less selected populations. Here, CDK4 is linked to interstitial lung disease.